Treatment of demyelinating disorders

A method of treating a demyelinating disorder comprising administering an effective amount of an inhibitor of the interaction of glutamate with the α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptor complex.

A method of treating a demyelinating disorder comprising administering a combination of an effective amount of an inhibitor of the interaction of glutamate with the α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptor complex combined with one or more agents selected from the group consisting of an immunosuppressive agent an interferon (IFN), a phosphodiesterase type IV inhibitor, a humanised monoclonal antibody against a leukocyte adhesion molecule, a synthetic polypeptide, a tissue matrix metalloproteinase (MMP) inhibitor, and a tumour necrosis factor (TNF) inhibitor.

31-37. (canceled)

A pharmaceutical composition for treating a demyelinating disorder comprising an inhibitor of the interaction of glutamate with the α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptor complex and a pharmaceutically acceptable carrier, wherein the inhibitor is combined with one or more agents selected from the group consisting of an immunosuppressive agent, an interferon (IFN), a phosphodiesterase type IV inhibitor, a humanised monoclonal antibody against a leukocyte adhesion molecule, a synthetic polypeptide, a tissue matrix metalloproteinase (MMP) inhibitor, and a tumour necrosis factor (TNF) inhibitor.